SPECIAL JONES REPORT
This report highlights the basic steps to resolve the Covid -19 Pandemic crisis. I have examined the progress thus far in addressing the pandemic. For the point of expediency, I will cover each topic as succinctly as I can. The reader is encouraged to do their own research to study the facts as I present them. The ultimate answer to Covid 19 and the recent mutant is a viable vaccine.
There are several vaccine candidates in clinical trials being fostered by the Trump Operation Warp Speed (OWS) team. Each has some attributes the merit further research. Also, not widely publicized are FDA hurdles in current candidates in the safety profile that must be passed. Some experts are doubtful that Moderna and Pfizer versions will pass the Adverse effects phase. However, there is one vaccine made by Inovio Pharmaceuticals that has already had success against a similar Corona virus called MERS with INO4700. It did not make it to market because the economic advantage was not there after MERS faded. However Covid 19 is not fading. INO4800 has a very similar profile and is expected by Inovio to be equally safe and effective. Indeed, the DoD through the Pentagon has already purchased $71 Million worth of " Cellectra" devices used in the " electroportation" to easily administer the INO4800 vaccine to the US Military. Further, the DoD has arranged for a private Plasmid company, Ology, to work with Inovio to produce INO4800 for clinical trials. Inovio is currently in a Phase 1 trial and recently expanded it to include senior citizens, the highest "at risk" population.
The study of this report has forced me to come to one conclusion. In order to address the global Covid 19 pandemic, immediate steps are required to advance Inovio's INO4800 vaccine beyond the initial steps taken by the Pentagon for just the US Military. These steps are as follows:
1. Immediate funding by OWS to Inovio Pharmaceuticals to lead the imminent next phase 2/3 clinical trials to advance INO4800 in America and the rest of the world.
2. Inovio and DNA Plasmid manufacture, VGXI, to settle disputes by the following proposal arrangement. VGXI is on track to expand their US facilities to mass produce DNA plasmids such as INO4800. Their web site expresses a willingness to continue to work with Inovio. Part of the law suit involves the Inovio DoD contract with Ology. This proposal is to have parties agree to the following and drop all court cases:
3. Inovio/ Ology - Provides INO 4800 to the Pentagon and US military as the current contract states. Inovio provides Cellectras as purchased via the DoD.
4. Inovio/ VGXI - Provides INO4800 to the general US population as needed. It would be imperative that VGXI expand their planned facilities faster that currently planned. It is noted that VGXI is a subsidiary of the parent company, Geneone Life science Company in South Korea.
5. Inovio/ Geneone Life science - Provides INO 4800 for Asia. all of Asia that wants it.
6. Inovio/ Richter Helm - Provides INO 4800 for all of Europe that requests it.
This plan assumes that all parties above will agree and work as ONE cohesive unit led by Inovio Pharmaceuticals. Where there are shortfalls in one plan, the others will help.
Conclusion:
Covid 19 and the more recent mutant version is not waiting. Time is of the essence. I urge responsible parties above to consider such a plan, modify as needed and start executing soon. This is an example of a plan and can be modified and expanded as needed to meet the global demand for a safe and effective vaccine that strong evidence is pointing to Inovio's INO4800.
Recent Results from Inovio (INO):
- INO-4800 showed durable antibody and T cell responses in rhesus macaques for 4 months
-
INO-4800 is the only vaccine to demonstrate long-term protection in
non-human primates challenged with SARS-CoV-2 virus 13 weeks from
vaccination
- Memory T and B cell responses resulted in reduced viral loads and faster viral clearance in macaques' lungs and nasal passages
-
INO-4800 vaccination generated antibodies neutralizing both the earlier
strain of virus as well as the mutant variant (D614G) that has emerged
with greater infectivity, and now accounts for >80% of newly
circulating virus
- No antibody-dependent enhanced disease events were reported
Commentary:
Will the world get the flick in time?
____-
All in my humble opinion, scroll down and read more..
This site does NOT make Buy / Sell recommendations.
___
